0001171843-23-006716.txt : 20231103 0001171843-23-006716.hdr.sgml : 20231103 20231103121447 ACCESSION NUMBER: 0001171843-23-006716 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231103 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231103 DATE AS OF CHANGE: 20231103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 231375192 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_110323.htm FORM 8-K Form 8-K
0000882796 False 0000882796 2023-11-03 2023-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 3, 2023

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware000-2318662-1413174
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockBCRXNasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 7.01. Regulation FD Disclosure.

On November 3, 2023, BioCryst Pharmaceuticals, Inc. (the “Company”) and Clearside Biomedical, Inc. (“Clearside”) issued a press release announcing a license agreement enabling the Company to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector® to deliver avoralstat directly to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema.

A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 BioCryst Pharmaceuticals, Inc.
   
  
Date: November 3, 2023By: /s/ Alane Barnes        
  Alane Barnes
  Chief Legal Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space –

– BioCryst to host R&D Day today at 1:00 pm ET –

ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Clearside Biomedical, Inc. (Nasdaq: CLSD) today announced the entry into a license agreement enabling BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector® to deliver avoralstat directly to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema (DME).

“Many DME patients are not effectively controlled with anti-VEGF therapy, so it is exciting to target plasma kallikrein by combining avoralstat with delivery into the suprachoroidal space using Clearside’s proprietary SCS Microinjector. Our collaboration provides an opportunity for us to advance the development of avoralstat into a proof-of-concept trial as a potential best-in-class medicine that can offer new hope to patients living with DME,” said Jon Stonehouse, president and chief executive officer of BioCryst.

Avoralstat has high potency and low solubility, which are two characteristics important to achieving potential efficacy with reduced dosing frequency in the eye for DME patients. Delivering avoralstat directly into the suprachoroidal space could allow avoralstat to inhibit plasma kallikrein at the sites of edema formation in DME disease, the retinal and choroidal vascular endothelium.

Avoralstat was previously evaluated in an oral formulation in a Phase 3 clinical trial in patients with hereditary angioedema (HAE). In the HAE clinical trial program in 276 individuals, oral avoralstat was safe and well tolerated with an adverse event profile similar to placebo.

“Treating patients with DME by delivering avoralstat directly to the suprachoroidal space using the SCS Microinjector expands the reach of our proprietary SCS injection platform to a greater number of patients. We are proud to partner with BioCryst to help bring a potential new treatment to patients who are underserved by current therapies for DME,” said George Lasezkay, Pharm.D., J.D., president and chief executive officer of Clearside.

Under the terms of the agreement, Clearside will receive a $5 million upfront license fee from BioCryst. Clearside is eligible to receive up to an additional $30 million in clinical and regulatory milestone payments, and up to a total of $47.5 million in three post-approval sales-based milestone payments as annual global net sales progress to $2 billion.

BioCryst will pay Clearside tiered mid-single digit royalties on annual global net product sales, at three tiers, including a top tier of >$1.5 billion.

DME is the most common cause of vision loss in individuals with diabetes and at least one-third of patients have persistent DME despite treatment with anti-VEGF therapies, which are administered via monthly injection. Data have shown that elevated kallikrein may be a cause of non-response to anti-VEGF therapy.

BioCryst R&D Day
BioCryst will host a Research and Development (R&D) Day at 1:00 pm ET today at its Discovery Center of Excellence in Birmingham, AL. At the R&D Day, BioCryst plans to describe its drug discovery process and introduce additional therapies from its pipeline. The live webcast and replay of the R&D Day will be available online in the investors section of the BioCryst website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform utilizes its patented SCS Microinjector®, the first and only FDA-approved way to access the suprachoroidal space. Clearside’s SCS Microinjector enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. Clearside’s lead suprachoroidal development program, CLS-AX (axitinib injectable suspension), is in Phase 2b clinical testing for the treatment of neovascular age-related macular degeneration (wet AMD). Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com.

BioCryst Pharmaceuticals, Inc. Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding BioCryst’s plans and expectations for avoralstat. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on product candidates, may impose a clinical hold with respect to product candidates, or may withhold or delay market approval for product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates, manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

Clearside Biomedical, Inc. Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the potential benefits of product candidates delivered using Clearside’s SCS Microinjector®. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC) on March 14, 2023, Clearside’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 filed with the SEC on August 14, 2023 and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

BCRXW

BioCryst Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Clearside Biomedical Contacts:
Jenny Kobin
Remy Bernarda
+ 1 678 430 8206
ir@clearsidebio.com

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 03, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 03, 2023
Entity File Number 000-23186
Entity Registrant Name BioCryst Pharmaceuticals, Inc.
Entity Central Index Key 0000882796
Entity Tax Identification Number 62-1413174
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4505 Emperor Blvd., Suite 200
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27703
City Area Code 919
Local Phone Number 859-1302
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_110323_htm.xml IDEA: XBRL DOCUMENT 0000882796 2023-11-03 2023-11-03 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2023-11-03 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_110323.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_110323.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_110323.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_110323.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_110323.htm", "first": true, "unique": true } } }, "tag": { "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001171843-23-006716-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-006716-xbrl.zip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